Clostridium difficile infection (CDI) is a common bacterial infection that affects the digestive tract, causing symptoms such as diarrhea, abdominal pain, and fever. Research indicates that CDI affects millions of people worldwide, with a significant impact on healthcare systems due to its recurrence and complications. CDI can lead to severe complications such as pseudomembranous colitis and toxic megacolon, especially in vulnerable populations like elderly individuals and those with weakened immune systems.

This study will evaluate the safety and effectiveness of LMN-201, an investigational drug that might prevent CDI reinfections by controlling or removing the “bad” bacteria. This study drug is swallowed as capsules. The capsules hold proteins carefully grown in spirulina, a blue-green algae rich in nutrients.

The potential benefits to participants would be study-related medical care at no-cost and knowledge gained about their condition. On a wider scale, there may be general benefits to society because the investigational treatment may become a future treatment option.

To qualify for the study, you must be:

• Male or female adult 19 years of age or older
• Diagnosed with C. Diff
• Taking or planning to take antibiotics for C. diff
• No known allergies to corn or spirulina
• Other criteria may apply*

*There are multiple studies available to participate in and each may require different criteria to be approved as a participant.

To learn more about this trial and to find out if you qualify, please call 402.934.0044 or complete the form on our Contact page.